 respons rate surviv primari system amyloidosi patient biopsy-proven primari system amyloidosi AL respons rate agent-bas chemotherapi patient serum creatinin concentr advers effect respons rate patient nephrot syndrom normal serum creatinin valu echocardiograph evid cardiac amyloidosi respons rate patient amyloid cardiomyopathi aliv year diagnosi none patient amyloid peripher neuropathi regress diseas median time respons month median surviv patient month year patient aliv minimum follow-up month seven acut leukemia dysmyelopoiet syndrom presum complic melphalan therapi group patient respons agent-bas therapi median surviv month year patient agent-bas chemotherapi AL benefici subset patient trial chemotherapi patient surviv benefit